31.08.2013 Views

Rivaroxaban for the treatment of deep vein thrombosis and ...

Rivaroxaban for the treatment of deep vein thrombosis and ...

Rivaroxaban for the treatment of deep vein thrombosis and ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

depends on <strong>the</strong> specific parameterisation. In addition, when <strong>the</strong>re is relatively little sample data being<br />

analysed, <strong>the</strong> prior in<strong>for</strong>mation can dominate <strong>and</strong> should be described with care.<br />

NICE DSU TSD2 states that it has become st<strong>and</strong>ard practice to use a uni<strong>for</strong>m prior distribution on <strong>the</strong><br />

range (0, 2) <strong>for</strong> <strong>the</strong> between-study st<strong>and</strong>ard deviation <strong>for</strong> log-odds ratios <strong>and</strong> log hazard ratios.<br />

However, <strong>the</strong> document also notes that <strong>the</strong>re are major disadvantages in routinely using vague prior<br />

distributions because, in <strong>the</strong> absence <strong>of</strong> a reasonable number <strong>of</strong> large trials, <strong>the</strong> posterior distribution<br />

<strong>of</strong> <strong>the</strong> between-study st<strong>and</strong>ard deviation will be poorly identified <strong>and</strong> likely to include values that are<br />

implausibly high or possibly implausibly low <strong>and</strong> will not represent reasonable beliefs.<br />

In this STA, <strong>the</strong> analyses were conducted using a uni<strong>for</strong>m prior distribution on <strong>the</strong> range (0, 5) <strong>for</strong> <strong>the</strong><br />

between-study st<strong>and</strong>ard deviation when analysing hazard ratios <strong>and</strong> odds ratios. Although this was<br />

taken from <strong>the</strong> WinBUGS code included in NICE DSU TSD2, it is even more extreme than that<br />

described with caution in Section 6.2. Half <strong>of</strong> <strong>the</strong> analyses included four or less data points <strong>and</strong> <strong>the</strong>re<br />

are not many more data points available in <strong>the</strong> primary analyses. Consequently, <strong>the</strong> prior distribution<br />

<strong>for</strong> <strong>the</strong> between-study st<strong>and</strong>ard deviation will have a large impact on <strong>the</strong> results. In fact, as a<br />

consequence <strong>of</strong> <strong>the</strong> prior distribution not representing genuine prior beliefs <strong>the</strong>n, without much<br />

Bayesian updating <strong>of</strong> <strong>the</strong> prior distribution <strong>for</strong> <strong>the</strong> between-study st<strong>and</strong>ard deviation to its posterior<br />

distribution, <strong>the</strong> posterior distributions <strong>for</strong> <strong>the</strong> <strong>treatment</strong> effects will not represent meaningful beliefs.<br />

In <strong>the</strong> clarification letter, <strong>the</strong> ERG attempted to encourage <strong>the</strong> manufacturer to consider using a more<br />

in<strong>for</strong>mative prior distribution <strong>for</strong> <strong>the</strong> between-study st<strong>and</strong>ard deviation so as to avoid implausible<br />

estimates <strong>of</strong> <strong>treatment</strong> effect. Un<strong>for</strong>tunately, this question was not interpreted as <strong>the</strong> ERG had<br />

intended. NICE DSU TSD2 discusses <strong>the</strong> use <strong>of</strong> alternative prior distributions <strong>for</strong> <strong>the</strong> between-study<br />

st<strong>and</strong>ard deviation when <strong>the</strong>re are a limited number <strong>of</strong> studies. The ERG believes that a uni<strong>for</strong>m prior<br />

distribution on <strong>the</strong> range (0, 0.6) would have provided a more reasonable choice <strong>for</strong> <strong>the</strong> between-study<br />

st<strong>and</strong>ard deviation in <strong>the</strong> absence <strong>of</strong> a reasonable number <strong>of</strong> studies; this prior distribution is still<br />

reasonably uncertain <strong>and</strong> it acknowledges <strong>the</strong> possibility <strong>of</strong> moderate heterogeneity between studies.<br />

The ERG re-analysed <strong>the</strong> primary data using a uni<strong>for</strong>m prior distribution <strong>for</strong> <strong>the</strong> between-study<br />

st<strong>and</strong>ard deviation on <strong>the</strong> range (0, 5) as used in <strong>the</strong> MS, a uni<strong>for</strong>m prior distribution on <strong>the</strong> range (0,<br />

2), as recommended in NICE DSU TSD2, <strong>and</strong> a uni<strong>for</strong>m prior distribution on <strong>the</strong> range (0, 0.6) as a<br />

sensitivity analysis. These analyses are presented in section 4.5.<br />

When using a uni<strong>for</strong>m prior distribution <strong>for</strong> <strong>the</strong> between-study st<strong>and</strong>ard deviation on <strong>the</strong> range (0, 5)<br />

<strong>the</strong> means <strong>of</strong> <strong>the</strong> posterior distributions are greater than <strong>the</strong> 97.5%-iles, suggesting that <strong>the</strong><br />

distributions <strong>for</strong> <strong>the</strong> <strong>treatment</strong> effects are highly skew <strong>and</strong> essentially unstable.<br />

76<br />

Copyright 2012 Queen's Printer <strong>and</strong> Controller <strong>of</strong> HMSO. All rights reserved.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!